Tech Company Financing Transactions
Cyllene Therapeutics Funding Round
Andera Partners, Bpifrance and private investors participated in a $28.4 million Series B venture round for Cyllene Therapeutics. The round closed on 2/20/2025.
Transaction Overview
Company Name
Announced On
2/20/2025
Transaction Type
Venture Equity
Amount
$28,400,000
Round
Series B
Investors
Andera Partners (Lead Investor) (Raphaël Wisniewski)
Bpifrance (Lead Investor) (Benoît Barteau)
Proceeds Purpose
This funding allows us to advance our first program focussed on dysfunctions of the bladder, such as neurogenic bladder, through its initial clinical trial.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
13 rue Watt
Paris, 75013
France
Paris, 75013
France
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Cyllene Therapeutics is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy. Developing next generation DNA medicines to provide safe, efficacious, and affordable therapies to patients with severe localized chronic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Philippe Chambon
Chief Marketing Officer
Cornelia Molkenteller
Chief Operating Officer
Samuel Salot
Chief Scientific Officer
Alberto Epstein
Co-Founder
Pierre Denys
Co-Founder
François Giuliano
Co-Founder
Charles Joussain
VP - Bus. Development
Mikael Contrastin
VP - R & D
Teddy Jégu
VP - R & D
Astrid Valles-Sanchez
Browse more venture capital transactions:
Prev: 2/20/2025: OpenEvidence venture capital transaction
Next: 2/20/2025: Unit Network venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs